

S/N Unknown

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	John Edward More et al.	Examiner:	Unknown
Serial No.:	Unknown	Group Art Unit:	Unknown
Filed:	Herewith	Docket:	697.004US2
Title:	PURIFICATION METHOD		
(Continuation of U.S. Application Serial No. 09/142,348, filed 01/25/1999)			

PRELIMINARY AMENDMENT

Commissioner for Patents
Washington, D.C. 20231

Prior to examination, please amend the above-identified continuation application as follows.

In the Specification

On page 1, after the title, please insert the following section:

--CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. Application Serial No. 09/142,348 filed September 8, 1998 (102(e) date: January 25, 1999), which is a U.S. National Stage filing of International Application No. PCT/GB97/ 00642 filed March 7, 1997 and published in English as WO 97/32893 on September 12 1997, which claimed priority under 35 USC 119 from British Application No. 9604921.8 filed March 8, 1996; which applications are incorporated herein by reference.--

In the Claims

Please cancel original claims 1-26 without prejudice.

Please add the following new claims 27-34:

27. (New) AAG substantially free of LPS, said AAG having a LPS concentration of less than or equal to 0.1 Eu/mg AAG.
28. (New) AAG as claimed in claim 27 wherein the AAG has a LPS level of less than 0.075 Eu/mg AAG.

PRELIMINARY AMENDMENT

Serial Number: Unknown

Filing Date: Herewith

Title: PURIFICATION METHOD

Page 2

Dkt: 697.004US2

29. (New) AAG as claimed in claim 27 wherein the AAG has a LPS level of less than 0.050 Eu/mg AAG.
30. (New) A virus inactivated or a virus depleted preparation of AAG as defined in claim 27.
31. (New) AAG as defined in claim 27 for use in therapy.
32. (New) AAG as defined in claim 27 for use in treatment of drug toxicity.
33. (New) The use of AAG as defined in claim 27 in the manufacture of a medicament for use in the treatment of drug toxicity.
34. (New) A pharmaceutical composition comprising AAG as defined in claim 27 together with one or more pharmaceutically acceptable carriers or excipients.

Remarks

Claims 1-26 have been cancelled, and claims 27-34 have been added. Claims 27-34 are now pending.

The Examiner is invited to contact Applicants' undersigned representative if there are any questions regarding this Preliminary Amendment.


Respectfully submitted,

JOHN EDWARD MORE ET AL.

By their Representatives,

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.
P.O. Box 2938
Minneapolis, MN 55402
(612) 371-2106

Date 25 February 2002

By 
Katharine A. Jackson Huebsch
Reg. No. 47,670

"Express Mail" mailing label number: EV 019 078 228 US

Date of Deposit: February 26, 2002

This paper or fee is being deposited on the date indicated above with the United States Postal Service pursuant to 37 CFR 1.10, and is addressed to the Commissioner for Patents, Box Patent Application, Washington, D.C. 20231.

20020226 095252